Azvudine

Azvudine
Clinical data
Trade names	捷倍安, 双新艾克
Other names	2′-Deoxy-2′-β-fluoro-4′-azidocytidine (FNC), RO-0622
Legal status
Legal status	US: Investigational drug; CN: Conditional use Rx;
Pharmacokinetic data
Bioavailability	83% (rat, dog)
Metabolism	liver (CYP3A)
Elimination half-life	4 hours (dog)
Identifiers
	IUPAC name 4-Amino-1-[(2R,3S,4R,5R)-5-azido-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;
CAS Number	1011529-10-4 ;
PubChem CID	24769759;
DrugBank	DB16407;
ChemSpider	24717759;
UNII	IJ2XP0ID0K;
ChEMBL	ChEMBL519846;
Chemical and physical data
Formula	C9H11FN6O4
Molar mass	286.223 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@](O2)(CO)N=[N+]=[N-])O)F;
	InChI InChI=1S/C9H11FN6O4/c10-5-6(18)9(3-17,14-15-12)20-7(5)16-2-1-4(11)13-8(16)19/h1-2,5-7,17-18H,3H2,(H2,11,13,19)/t5-,6-,7+,9+/m0/s1; Key:KTOLOIKYVCHRJW-XZMZPDFPSA-N;

Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. It was discovered for the treatment of hepatitis C and has since been investigated for use against other viral diseases such as AIDS and COVID-19, for which it was granted conditional approval in China.

Azvudine was first discovered in 2007. It costs 350 Chinese yuan per 7 days for COVID, as of November 2022.